NanOlogy
  • Home
  • About
  • Technology
    • Overview
    • Purcision Technology
  • Development
    • Investigational Drugs
    • Pipeline
    • Clinical Trials
    • Partnering Opportunities
  • News & Publications
  • Contact Us
    • Partnering Opportunities
    • Physicians and Patients
February 19, 2019 in Home Page, Presentations

ASCO-GU19 Poster: Evaluation of Submicron Particle Docetaxel Directly Injected into Uro-Oncologic Xenografts

NanOlogy 1 Like Post Comments Off on ASCO-GU19 Poster: Evaluation of Submicron Particle Docetaxel Directly Injected into Uro-Oncologic Xenografts

ASCO-GU19 Poster: Evaluation of Submicron Particle Docetaxel Directly Injected into Uro-Oncologic Xenografts

Read More
Post placeholder image
January 15, 2019 in Presentations

SABCS 2018 Poster: Phase 1/2 Study of Topical SOR007 for Cutaneous Metastases

NanOlogy 0 Like Post Comments Off on SABCS 2018 Poster: Phase 1/2 Study of Topical SOR007 for Cutaneous Metastases

SABCS 2018 Poster: Phase 1/2 Study of Topical SOR007 for Cutaneous Metastases

Read More
Post placeholder image
June 4, 2018 in Presentations

ASCO 2018 Poster: NanoPac Inhalation Treatment of NSCLC in a Nude Rat Orthotopic Lung Cancer Model

NanOlogy 0 Like Post Comments Off on ASCO 2018 Poster: NanoPac Inhalation Treatment of NSCLC in a Nude Rat Orthotopic Lung Cancer Model

ASCO 2018 Poster: NanoPac Inhalation Treatment of NSCLC in a Nude Rat Orthotopic Lung Cancer Model

Read More
Prev12Next
NanOlogy

NanOlogy investigational drugs have not yet been proven to be safe and effective in accordance with the requirements of the U.S. FDA and are not approved by FDA or any other jurisdiction for commercial distribution. NanOlogy, NanoPac, and NanoDoce are trademarks of NanOlogy, LLC.    Purcision is a trademark to CritiTech, Inc.  © NanOlogy LLC      Legal